Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
10 hedge funds and large institutions have $1.99M invested in Checkpoint Therapeutics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.08% more ownership
Funds ownership: 0.19% → 0.27% (+0.08%)
4% less capital invested
Capital invested by funds: $2.07M → $1.99M (-$80K)
9% less funds holding
Funds holding: 11 → 10 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$321K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$313K |
| 3 |
BlackRock
New York
|
+$190K |
| 4 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$173K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$331K |
| 2 |
Goldman Sachs
New York
|
-$94K |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$45K |
| 4 |
Morgan Stanley
New York
|
-$21.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$9K |
CKPT Hedge Fund Activity: Q2 2018 in Review
10 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2018, worth a combined $1.99M — down 3.9% from $2.07M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CKPT and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Bainco International Investors, opening a new position worth an estimated $321K. The largest seller was Millennium Management, exiting entirely with an estimated $331K sold.
- 10 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2018, down from 11 in Q1 2018.
- Funds reported $1.99M of Checkpoint Therapeutics stock for Q2 2018, down 3.9% quarter-over-quarter.
- 4 funds opened new Checkpoint Therapeutics positions in Q2 2018 and 5 closed out, a net change of -1 holder.
- The largest Checkpoint Therapeutics buyer in Q2 2018 was Bainco International Investors, an estimated $321K added.
- The largest Checkpoint Therapeutics seller in Q2 2018 was Millennium Management, an estimated $331K sold.
Based on aggregated 13F filings for Q2 2018.